Clinicopathological and prognostic significance of phosphorylated PRAS40 (Thr246) in breast cancer

1. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, el al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554.10.1126/science.1096502Search in Google Scholar

2. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009; 9:550-62.10.1038/nrc2664Open DOISearch in Google Scholar

3. Hernandez-Aya LF, Gonzalez-Angulo AM.Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011; 16:404-14.10.1634/theoncologist.2010-0402Open DOISearch in Google Scholar

4. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, et al. Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors. Sci Transl Med. 2010; 2:43ra55.10.1126/scitranslmed.3001065Open DOISearch in Google Scholar

5. Bedard PL, Cardoso F, Piccart-Gebhart MJ. Stemming resistance to HER-2 targeted therapy. J Mammary Gland Biol Neoplasia. 2009; 14:55-66.10.1007/s10911-009-9116-xOpen DOISearch in Google Scholar

6. Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska- Seta I, Murawska M, Moes J, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009; 8:21-6.10.4161/cbt.8.1.7209Search in Google Scholar

7. Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res Treat. 2010; 124:1-11.10.1007/s10549-010-1108-4Search in Google Scholar

8. Moulder SL.Does the PI3K pathway play a role in basal breast cancer? Clin Breast Cancer. 2010; 10 Suppl 3: S66-71.10.3816/CBC.2010.s.014Open DOISearch in Google Scholar